Markku Miettinen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Gastrointestinal stromal tumors
    Markku Miettinen
    Laboratory of Pathology, NCI NIH, 9000 Rockville Pike, Building 10, Room 2B50, Bethesda, MD 20892, USA Electronic address
    Gastroenterol Clin North Am 42:399-415. 2013
  2. ncbi Claudin-5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas
    Markku Miettinen
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 35:1848-56. 2011
  3. ncbi A simple method for generating multitissue blocks without special equipment
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Appl Immunohistochem Mol Morphol 20:410-2. 2012
  4. ncbi Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:629-39. 2012
  5. ncbi Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda 20892, MD, USA
    Am J Surg Pathol 36:351-9. 2012
  6. ncbi Histopathology of gastrointestinal stromal tumor
    Markku Miettinen
    National Cancer Institute, Laboratory of Pathology, Bethesda, Maryland 20892, USA
    J Surg Oncol 104:865-73. 2011
  7. ncbi Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, 20892, USA
    Am J Surg Pathol 35:1712-21. 2011
  8. ncbi Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation
    Markku Miettinen
    Laboratory of Pathology Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute Genetics Branch of the National Institutes of Health National Cancer Institute, Bethesda, MD
    Am J Surg Pathol 37:234-40. 2013
  9. ncbi Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications
    Jerzy Lasota
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 37:114-9. 2013
  10. ncbi KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics
    Phyu Phyu Aung
    Laboratory of Pathology, National Institutes of Health, NCI, 10 Center Drive, Room 2B50, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:265-72. 2012

Collaborators

Detail Information

Publications12

  1. ncbi Gastrointestinal stromal tumors
    Markku Miettinen
    Laboratory of Pathology, NCI NIH, 9000 Rockville Pike, Building 10, Room 2B50, Bethesda, MD 20892, USA Electronic address
    Gastroenterol Clin North Am 42:399-415. 2013
    ..These are related to deficiencies in the succinate dehydrogenase complex, NF1-gene alterations in connection with neurofibromatosis type 1 tumor syndrome, and mutational activation of the BRAF oncogene in very rare cases...
  2. ncbi Claudin-5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas
    Markku Miettinen
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 35:1848-56. 2011
    ....
  3. ncbi A simple method for generating multitissue blocks without special equipment
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Appl Immunohistochem Mol Morphol 20:410-2. 2012
    ..This technique is especially suitable when abundant tissue is available, for example, generating blocks containing libraries of normal tissues or defined tumors for antibody screening or tumor immunophenotyping...
  4. ncbi Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:629-39. 2012
    ..Information on VEGFR2 tissue expression may be useful in development of targeted oncologic therapy through VEGFR2-specific tyrosine kinase inhibitors...
  5. ncbi Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda 20892, MD, USA
    Am J Surg Pathol 36:351-9. 2012
    ..Its patterns of expression in hemangiomas and angiosarcoma may be diagnostically useful and offer a new parameter in the biological classification of vascular tumors...
  6. ncbi Histopathology of gastrointestinal stromal tumor
    Markku Miettinen
    National Cancer Institute, Laboratory of Pathology, Bethesda, Maryland 20892, USA
    J Surg Oncol 104:865-73. 2011
    ..GISTs in NF1 patients and children are distinctive clinicopathologic groups. Immunohistochemical testing for KIT and sometimes for DOG1/Ano 1 is essential in confirming the diagnosis...
  7. ncbi Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age
    Markku Miettinen
    Laboratory of Pathology, National Cancer Institute, Bethesda, 20892, USA
    Am J Surg Pathol 35:1712-21. 2011
    ....
  8. ncbi Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation
    Markku Miettinen
    Laboratory of Pathology Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute Genetics Branch of the National Institutes of Health National Cancer Institute, Bethesda, MD
    Am J Surg Pathol 37:234-40. 2013
    ..SDHA-negative GISTs comprise approximately 30% of SDHB-negative/SDH-deficient GISTs, and SDHA loss generally correlates with SDHA mutations...
  9. ncbi Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications
    Jerzy Lasota
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 37:114-9. 2013
    ..Because inhibition of IGF1R signaling might become a therapeutic target in GISTs, screening for IGF1R expression may become important in the near future...
  10. ncbi KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics
    Phyu Phyu Aung
    Laboratory of Pathology, National Institutes of Health, NCI, 10 Center Drive, Room 2B50, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:265-72. 2012
    ..PNL2 is highly specific for melanomas but lacks reactivity with desmoplastic melanomas. It is also an excellent supplementary marker for perivascular epitheloid cell tumor at various sites...
  11. ncbi [Gastrointestinal stromal tumor]
    Markku Miettinen
    Laboratory of Pathology National Cancer Institute NIH, Bethesda, Maryland, USA
    Duodecim 128:1441-50. 2012
    ..Loss of succinate dehydrogenase complex is a newly understood pathogenesis for 5% of GIST, associated with early onset of disease...
  12. ncbi Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors: a diagnostic pitfall
    Stephanie Barak
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:1404-9. 2012
    ....